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n their recent paper, Ridker et al. (1) performed a secondary
nalysis of JUPITER (Justification for the Use of Statins in
revention–an Intervention Trial Evaluating Rosuvastatin) to
ssess the efficacy of rosuvastatin for primary prevention in patients
ith moderate chronic kidney disease (CKD). According to their
esults, rosuvastatin reduces first cardiovascular events and all-
ause mortality among men and women with low-density lipopro-
ein cholesterol 130 mg/dl, elevated high-sensitivity C-reactive
rotein, and moderate CKD (estimated glomerular filtration rate
60 ml/min/1.73 m2).
The authors’ results are in accordance with previous secondary/
ost hoc analyses of major secondary prevention statin trials. In
articular, the HPS (Heart Protection Study) (2), the CARE
Cholesterol And Recurrent Events) study (3), and the Pravastatin
ooling Project (4) suggested a beneficial effect of statins on
ardiovascular end points. Conversely, both the PREVENT IT
Prevention of Renal and Vascular End Stage Disease Intervention
rial) (5)—the only prospective randomized trial evaluating the
ole of statins in patients with mild CKD—and ALERT (Assess-
ent of Lescol in Renal Transplant Trial) (6) failed to detect any
ardiovascular benefit of statins in nondialysis CKD patients. To
urther complicate things, a recent meta-analysis involving 25,017
re-dialysis patients concluded that statins significantly reduced
he all-cause and cardiovascular mortality (7).
The results of this secondary analysis of the JUPITER trial
hould be interpreted with caution for the following reasons. First,
he JUPITER trial enrolled patients without overt diabetes mel-
itus, in contrast to the 4D (Die Deutsche Diabetes Dialyse) study,
hich employed diabetic dialysis patients (8). Moreover, in
URORA (A Study to Evaluate the Use of Rosuvastatin in
ubjects on Regular Hemodialysis: An Assessment of Survival and
ardiovascular Events), there was an almost statistically significant
redominance of patients with diabetes or diabetic nephropathy as
he cause of end-stage renal disease in the statin group (9). Because
iabetes is an independent cardiovascular risk factor, statins might
ot confer any benefit in terms of primary prevention in diabetic
KD patients. Second, of 3,267 patients included in the study,
nly 14 had stage IV CKD. It is well established that cardiovas-
ular mortality increases progressively through the stages of CKD
10), and thus it might be too late for statins to provide any benefit
n stage IV to V CKD patients. Therefore, the findings of this
nalysis cannot be extrapolated to patients with CKD and diabetes
r beyond stage III CKD.
Regarding the effects of statins on renal function, the present
tudy did not detect a significant difference in the change of
stimated glomerular filtration rate between the rosuvastatin and
he placebo arms after 1 year of follow-up. However, the follow-up
as short, and again, this study enrolled almost only a specific
ubgroup of CKD patients (stage III CKD). It should be noted
hat data from secondary/post hoc analyses of the major statin
rials are more robust in supporting a renoprotective effect oftatins in CKD patients compared with their cardioprotective
ffects (11), whereas 2 recent large meta-analyses did not show an
mpact of statins on glomerular filtration rate (7,12).
Given the conflicting findings on the cardioprotective and
enoprotective role of statins along with their potentially harmful
ffects (13), the results of SHARP (Study of Heart and Renal
rotection) (14) and PLANET (Prospective Evaluation of Pro-
einuria and Renal Function in Diabetic Patients With Progressive
enal Disease Trial) (15) are eagerly anticipated.
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